Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group by Guadalupe Oñate, Ana Garrido, Montserrat Arnan, Helena Pomares, Ester Alonso, Mar Tormo, Marina Diaz-Beya, Susana Vives, Lurdes Zamora, Antonia Sampol, Rosa Coll, Olga Salamero, Marta Cervera, Antoni Garcia, Ferran Vall-Llovera, Sara Garcia-Avila, Joan Bargay, Xavier Ortin, Eva Iranzo, Francisca Guijarro, Marta Pratcorona, Josep F. Nomdedeu, Jordi Esteve, Jorge Sierra

Get full text

High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience by Veronica González‐Calle, Paula Rodriguez‐Otero, Maria J. Calasanz, Manuela Guijarro, Joaquin Martínez‐López, Laura Rosiñol, Miguel T. Hernández, Ana I. Teruel, Mercedes Gironella, Albert Oriol, Javier de laRubia, Ana P. González‐Rodríguez, Joan Bargay, Felipe deArriba, Luis Palomera, Marta‐Sonia González‐Pérez, Anna Sureda, Enrique Ocio, Juan J. Lahuerta, Joan Bladé, Jesus F. San Miguel, Maria V. Mateos, Norma C. Gutiérrez

Get full text